“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Developing new chemical entities for focused therapy areas
Producing quality medicines in areas of unmet needs
Producing high quality affordable and accessible biologics
Financial Result
Share Capital
Press Releases
Press Kit
BSE -
NSE -
Fiscal year 2019 Results
Board recommends dividend of 250%
Mumbai, May 15, 2019: Pharma major Lupin Limited reported its financial performance for the fourth quarter and fiscal year ending March 31st, 2019. These audited results were taken on record by the Board of Directors at a meeting held in Mumbai today.
Key Financial & Performance Highlights
Commenting on the results, Mr. Nilesh Gupta, Managing Director, Lupin Limited said, “As committed, we have been able to deliver strong growth in operational performance through consecutive quarters. On the back of solid in-line sales and important new product launches like Ranolazine and Levothyroxine, the US generics business has bounced back strongly. Resolving the compliance issues at some of our sites and delivering on our cost optimization efforts is now imperative and as we start delivering on complex generics, markets like US and India will drive our growth.”
Consolidated Audited Financial Results – FY2019
Amount in INR m.
[1] Sales for FY2019 include NCE Licensing Income of INR 2,103 m. on license of Lupin’s MALT1 inhibitor to AbbVie Inc
[2] Includes provision of INR 3,400 m. for fine related to Perindopril Litigation
[3] In FY2018 the Company made impairment provision of INR 14,644 m. on certain intangible assets acquired as a part of the Gavis group acquisition
[4] Deferred tax includes deferred tax assets of INR 3,223 m. created on difference between tax and book value of certain intangible assets of Gavis
Consolidated Audited Financial Results – Quarter IV FY2019
[1] Sales for Q3FY2019 include NCE Licensing Income of INR 2,103 m. on license of Lupin’s MALT1 inhibitors to AbbVie Inc
[2] Includes provision for fine related to Perindopril Litigation
Income Statement highlights – Q4 FY2019
Q3 FY2019
Balance Sheet highlights
Sales Mix
Operational Highlights
North America
North America sales in FY2019 were INR 55,924 m. compared to INR 58,939 m. in FY2018; accounting for 34% of global sales. Q4 FY2019 sales increased by 22.8% to INR 17,406 m. compared to Q3 FY2019 and increased by 16.1% compared to Q4 FY2018.
India
India business sales in FY2019 increased by 12.4% to INR 46,382 m. compared to FY2018; accounting for 29% of global sales. Q4 FY2019 sales were INR 10,525 m. compared to INR 11,902 m. in Q3 FY2019 and INR 9,647 m. in Q4 FY2018.
Lupin is the 5th largest company in the Indian Pharmaceutical Market (IQVIA MAT Mar 2019).
Asia-Pacific (APAC)
APAC business sales in FY2019 increased by 1.5% to INR 26,144 m. compared to FY2018; accounting for 16% of global sales. Q4 FY2019 sales were INR 6,901 m. compared to INR 6,936 m. in Q3 FY2019 and INR 6,637 m. in Q4 FY2018.
Lupin’s Japan FY2019 sales increased by 8.3% to JPY 33,889 m. compared to FY2018. Q4 FY2019 sales were JPY 8,580 m. compared to JPY 9,028 in Q3 FY2019 and increased by 1% compared to Q4 FY2018.
Lupin is the 6th largest generic player in Japan (IQVIA MAT Mar 2019).
Lupin’s Philippines sales in FY2019 were PHP 1,696 m. compared to PHP 2,070 m. in FY2018. Q4 FY2019 sales were PHP 557 m. compared to PHP 404 m. in Q3 FY2019 and PHP 760 m. in Q4 FY2018.
Europe, Middle East and Africa (EMEA)
EMEA business sales in FY2019 increased by 5.8% to INR 11,906 m. compared to FY2018; accounting for 7% of global sales. Q4 FY2019 sales were INR 3,397 m. compared to INR 2,800 m. in Q3 FY2019 and INR 3,513 m. in Q4 FY2018.
Lupin’s South Africa sales in FY2019 increased by 11.1% to ZAR 1,162 m. compared to FY2018. Q4 FY2019 sales increased by 23.8% to ZAR 342 m. compared to Q3 FY2019 and increased by 10.3% compared to Q4 FY2018.
Lupin is the 4th largest generic player in the South African market (IQVIA MAT Mar 2019).
Lupin’s Germany sales in FY2019 were EUR 29 m. compared to EUR 31 m. in FY2018. Q4 FY2019 sales were EUR 7.1 m. compared to EUR 6.9 m. in Q3 FY2019 and EUR 8.1 m. in Q4 FY2018.
Latin America (LATAM)
LATAM business sales in FY2019 were INR 5,658 m. compared to INR 5,790 m. in FY2018; accounting for 4% of global sales. Q4 FY2019 sales were INR 1,385 m. compared to INR 1,557 m. in Q3 FY2019 and INR 1,645 m. in Q4 FY2018.
Lupin’s Brazil sales in FY2019 were BRL 145 m. compared to BRL 157 m. in FY2018. Q4 FY2019 sales were BRL 36 m. compared to BRL 42 m. in Q3 FY2019 and BRL 44 m. in Q4 FY2018.
Lupin’s Mexico sales in FY2019 increased by 4.9% to MXN 674 m. compared to FY2018. Q4 FY2019 sales increased by 3.5% to MXN 178 m. compared to Q3 FY2019 and increased by 6.9% compared to Q4 FY2018.
Global API
Global API business increased by 23.2% to INR 13,464 m. compared to FY2018; accounting for 8% of global sales. Q4 FY2019 sales were INR 2,912 m. compared to INR 3,624 m. in Q3 FY2019 and INR 2,808 m. in Q4 FY2018.
Research and Development
Revenue Expenditure on R&D for FY2019 amounted to INR 15,731 m., 9.6% of sales as against INR 18,510 m., 11.9% of sales for FY2018. Revenue expenditure on R&D for Q4 FY2019 amounted to INR 3,963 m., 9.2% of sales.
Lupin filed 27 ANDAs and received 30 ANDA approvals from the U.S. FDA during the year. Cumulative ANDA filings with the U.S. FDA stand at 422 as of March 31st, 2019, with the company having received 265 approvals to date. The Company now has 40 First-to-Files (FTF) filings including 15 exclusive FTF opportunities. Cumulative DMF filings stand at 201 as of March 31st, 2019.
The Company filed 3 MAA and received 1 approval from the European authority during the year. Cumulative filings with European authorities now stand at 59 with the company having received 55 approvals to date.
About Lupin Limited
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded and generic formulations, biosimilar products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
Lupin is the 8th largest generics pharmaceutical company by revenues (31st Dec 2018, Bloomberg LTM). The Company is the 3rd largest pharmaceutical player in the US by prescriptions (IQVIA MAT Mar 2019); 3rd largest Indian pharmaceutical company by global revenues (31st Dec 2018, Bloomberg LTM); 5th largest company in the Indian Pharmaceutical Market and 6th largest generic pharmaceutical player in Japan (IQVIA MAT Mar 2019).
For the financial year ended 31st March 2019, Lupin’s Consolidated sales and Net profits before exceptional items were at INR 163,694 million (USD 2.34 billion) and INR 9,466 million (USD 136 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter at – www.twitter.com/lupinglobal
CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.
For further information or queries please contact –
Safe Harbor Statement